About ABVC BioPharma, Inc.
https://www.abvcpharma.comABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
CEO
Uttam Yashwant Patil
Compensation Summary
(Year 2010)
Salary $200,000
All Other Compensation $22,023
Total Compensation $222,023
Industry Biotechnology
Sector Healthcare
Went public November 10, 2004
Method of going public IPO
Full time employees 16
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-07-25 | Reverse | 1:10 |
| 2019-05-20 | Reverse | 1:18 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 2
Overall Score 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $32.60 M
52w High $5.48
52w Low $0.40
P/E -7.43
Volume 19.59K
Outstanding Shares 14.49M
About ABVC BioPharma, Inc.
https://www.abvcpharma.comABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $795.95K ▲ | $1.96M ▼ | $-1.25M ▲ | -156.61% ▼ | $-0.05 ▲ | $-1.28M ▲ |
| Q2-2025 | $0 | $2.29M ▲ | $-2.26M ▼ | 0% | $-0.13 ▼ | $-2.1M ▼ |
| Q1-2025 | $0 ▼ | $693K ▲ | $-842.08K ▼ | 0% ▼ | $-0.06 ▼ | $-607.27K ▼ |
| Q4-2024 | $1.97K ▼ | $336.12K ▼ | $229.3K ▲ | 11.66K% ▲ | $0.02 ▲ | $-30.09K ▼ |
| Q3-2024 | $389.28K | $339.03K | $-186.56K | -47.93% | $-0.02 | $85.62K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $257.24K ▼ | $21.18M ▲ | $6.68M ▼ | $12.06M ▲ |
| Q2-2025 | $1.14M ▲ | $16.24M ▲ | $6.75M ▼ | $7.01M ▲ |
| Q1-2025 | $824.62K ▼ | $14.88M ▲ | $6.92M ▲ | $5.4M ▲ |
| Q4-2024 | $928.55K ▲ | $7.54M ▼ | $6.82M ▲ | $1.23M ▼ |
| Q3-2024 | $840.68K | $14.46M | $6.48M | $8.36M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.25M ▲ | $-133.26K ▲ | $-1.27M ▼ | $1.13M ▼ | $-222.41K ▼ | $-133.26K ▲ |
| Q2-2025 | $-2.26M ▼ | $-894.17K ▼ | $-665.78K ▼ | $1.93M ▲ | $316.76K ▲ | $-894.17K ▼ |
| Q1-2025 | $-944.19K ▼ | $-539.83K ▼ | $0 | $428.76K ▼ | $-104.25K ▼ | $-539.83K ▼ |
| Q4-2024 | $229.3K ▲ | $-493.61K ▼ | $0 | $581.46K ▲ | $93.94K ▲ | $-493.61K ▼ |
| Q3-2024 | $-186.56K | $171.72K | $0 | $-145.39K | $27.1K | $171.72K |
CEO
Uttam Yashwant Patil
Compensation Summary
(Year 2010)
Salary $200,000
All Other Compensation $22,023
Total Compensation $222,023
Industry Biotechnology
Sector Healthcare
Went public November 10, 2004
Method of going public IPO
Full time employees 16
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-07-25 | Reverse | 1:10 |
| 2019-05-20 | Reverse | 1:18 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 3
Price To Earnings 1
Price To Book 2
Overall Score 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0